Vorasidenib, sold under the brand name Voranigo, will be listed on the Pharmaceutical Benefits Scheme (PBS) for patients with IDH-mutant astrocytoma or oligodendroglioma, according to Health Minister Mark Butler. The listing marks the first breakthrough treatment for this rare, incurable brain cancer in more than 20 years, saving patients tens of thousands of dollars a month.
PBS Listing Slashes Cost of Voranigo for Brain Cancer Patients
The PBS subsidy drops the cost of the medication to a maximum of $25 per script, or $7.70 for concession cardholders. Without the government scheme, patients would pay up to $28,000 for a 30-day supply of the treatment, according to Health Minister Mark Butler.
Health Minister Mark Butler noted that the subsidised medicine will benefit about 135 Australians diagnosed with the condition each year. These rare brain tumors are the most common malignant primary brain tumors in adults under 50, affecting an estimated 3,230 Australians according to manufacturer Servier.
How Vorasidenib Targets IDH-Mutant Glioma
Patients are typically diagnosed between 20 and 45 years of age. Symptoms develop and worsen over many years, including seizures, cognitive changes, physical disability, and loss of independence. Prior to the approval of vorasidenib, clinical options were limited to surgery, ongoing monitoring, and radiation or chemotherapy to slow disease progression.
Vorasidenib works by treating cancers with mutations in the IDH1 or IDH2 genes. These mutations cause abnormal proteins to form and drive cancer growth. The drug blocks these mutated proteins to slow or stop the tumor from expanding.
Clinical Perspectives on Long-Term Care
“This is the first new treatment in 20 years being listed for a rare brain cancer, which can slow disease progression,” Health Minister Mark Butler said.
Peter MacCallum Cancer Centre medical oncologist Associate Professor Jim Whittle explained the complex realities of managing the condition. “For people living with IDH-mutant glioma, managing the disease involves making complex treatment decisions over many years,” he said. He added that care balances long-term disease control with preserving neurological function and quality of life, and the new drug provides patients with a vital treatment choice.
Did you know? While rare, IDH-mutant astrocytoma and oligodendroglioma represent the most common malignant primary brain tumors diagnosed in adults under 50.
Multidisciplinary Support and Side Effect Management
Australian Brain Tumour Collaborative spokesperson Craig Cardinal described the PBS listing as a significant milestone for the community. “Access to treatment is only one part of the journey,” Cardinal said, emphasizing that families also require coordinated multidisciplinary care, psychosocial support, and practical services throughout the diagnosis.
Servier Australia and New Zealand general manager Mélanie Chamaux welcomed the listing as a collective achievement for the healthcare system. “We hope this milestone brings renewed confidence and optimism to those facing the challenges of this disease,” Chamaux said.
Patients taking vorasidenib may experience increased liver enzymes, fatigue, headaches, diarrhea, nausea, and muscle aches and stiffness, according to manufacturer safety guidelines. Servier advises that liver function must be monitored before and throughout the course of treatment, and patients should consult their specialists to review their specific care options.
Frequently Asked Questions
Who is eligible for subsidised vorasidenib on the PBS?
The drug is listed for individuals living with IDH-mutant astrocytoma or oligodendroglioma.
How much will Voranigo cost under the PBS?
Patients will pay a maximum of $25 per script, or $7.70 for holders of a concession card, down from a monthly private cost of up to $28,000.
What are the common side effects of vorasidenib?
Reported side effects include increased liver enzymes, fatigue, headache, diarrhea, nausea, muscle aches, and stiffness. Regular liver function monitoring is required during treatment.
Take the Next Step: Have questions about navigating treatment options or accessing PBS-listed medications? Leave a comment below or subscribe to our newsletter for regular updates on healthcare policy and medical breakthroughs.
Worth a look